The Weekly Briefing
The Everhealth Weekly
Evidence-based intelligence for preventing chronic disease and extending healthspan.
Good morning,
One study has dominated women’s health feeds this week: an 18-year study linking the age of menopause to how the brain ages decades later. Women who reached menopause earlier showed faster memory decline, an earlier Alzheimer’s diagnosis, and more small-vessel changes on brain MRI.
That finding lands in the middle of the biggest shift in menopause care in twenty years. In February, the FDA removed the long-standing “black box” warnings on most menopausal hormone therapy. New autopsy data from Stanford tie estrogen therapy to fewer Alzheimer’s changes in the brain, while the largest reviews find hormone therapy neither raises nor lowers dementia risk for most women.
This edition sorts the signal from the noise: what menopause timing tells you about your brain, who benefits from hormone therapy and when, and what evidence-based hormone optimization actually looks like. That’s Section 3.
— The Everhealth Institute team
This Week in the Evidence
1. Earlier menopause linked to faster memory decline, earlier Alzheimer’s, and more brain “small-vessel” damage
Researchers from UCSF and Rush University, led by Drs. Maria Pia Campagna and Riley Bove, followed 2,603 women with yearly memory testing, clinical diagnoses, repeated brain MRI in a subset, and brain autopsy in more than 1,200 participants. They asked one question: does the age at which menopause occurred predict how the brain ages decades later?
It did, modestly but consistently. Each year earlier that menopause occurred was associated with slightly faster decline in global cognition and episodic memory. Alzheimer’s diagnosis came earlier too: menopause 10 years earlier corresponded to about 1.8 fewer Alzheimer’s-free years (average age at diagnosis was 88.4). The most striking finding was on MRI. Among women with natural menopause, reaching menopause 5 years earlier was associated with roughly 15% more white matter hyperintensity volume over the following decade. These bright spots on MRI largely reflect damage to the brain’s small blood vessels. Loss of total brain volume was present but small. Structural effects were strongest after natural (spontaneous) menopause rather than surgical menopause.
Source: Campagna MP, … Bennett DA, Bove R. Age at menopause and brain atrophy among older women. JAMA Netw Open. 2026;9(8):e2630973. doi:10.1001/jamanetworkopen.2026.30973 → · Free full text → · Medscape coverage → · ScienceAlert summary →
2. The FDA removed the “black box” warnings on menopausal hormone therapy, and put timing on the label
The 2003 boxed warnings were based on the Women’s Health Initiative (WHI), which enrolled women with an average age of 63, most of them many years past menopause. The FDA has now removed the boxed language on cardiovascular disease, breast cancer, and probable dementia. The dementia warning came from a trial of women aged 65 and older, not the 45–55-year-olds who typically start therapy. New labeling adds WHI data for women aged 50–59 and advises considering therapy for moderate-to-severe hot flashes within 10 years of menopause or before age 60. One boxed warning remains: estrogen alone raises endometrial cancer risk in women who still have a uterus, which is why they also need a progestogen.
Sources: Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. 2025. doi:10.1001/jama.2025.22259 → · FDA announcement → · Society of Gynecologic Oncology statement → · Cedars-Sinai perspective →
3. Estrogen-only therapy linked to fewer Alzheimer’s changes in the brain at autopsy
Stanford Medicine researchers led by Drs. Jennifer Bruno, Jacob Shaw and Hadi Hosseini went to the most definitive measure available: amyloid plaques and tau tangles in autopsied brains. Women who had used estrogen-only therapy (most had had a hysterectomy) had significantly fewer of these Alzheimer’s hallmarks, and about 35% lower odds of Alzheimer’s pathology. In living participants, estrogen-only users had 39% lower odds of a clinical dementia diagnosis and scored better on memory and daily-function measures. Results were adjusted for age, APOE4, hypertension and education.
Source: Bruno J, Shaw J, … Hosseini H. Neurology. 2026. doi:10.1212/WNL.0000000000218413 → · Stanford Medicine release →
4. The best evidence says: hormone therapy started near menopause neither harms nor protects memory
A UCL-led review commissioned for the World Health Organization’s 2026 dementia-prevention guidelines pooled 15 studies of perimenopausal and postmenopausal women, including women with early menopause. It found no evidence that hormone therapy increases or decreases the risk of dementia or mild cognitive impairment. One study suggested possible harm from estrogen-only therapy started at 65 or older, with low certainty.
The KEEPS trial randomized recently menopausal women (within 3 years of their last period) to oral estrogen, a transdermal estradiol patch, or placebo for 4 years. Roughly 10 years later, the KEEPS Continuation study found no difference in cognition, good or bad, between groups. A 2026 preprint meta-analysis (not yet peer-reviewed) goes further, suggesting a possible small increase in dementia risk and advising against prescribing hormones for cognition.
Sources: Menopause hormone therapy and risk of mild cognitive impairment or dementia: a systematic review and meta-analysis. Lancet Healthy Longev. 2025;6(12):100803. Full text → · Gleason CE, … Manson JE, Kantarci K. Long-term cognitive effects of menopausal hormone therapy: KEEPS Continuation. PLoS Med. 2024;21(11):e1004435. Free full text → · 2026 preprint meta-analysis (medRxiv) →
5. For women with menopause before 45, hormone therapy is replacement, not optional
Premature ovarian insufficiency (POI) means loss of ovarian function before 40. It affects about 1% of women, and early menopause (40–45) is more common still, including after surgery or cancer treatment. International guidelines recommend hormone therapy from diagnosis until at least the usual age of menopause (about 51), whether or not a woman has symptoms, to reduce long-term risks to bone, heart and brain. Women with POI typically need higher estrogen doses than women at usual-age menopause. A 2026 FIGO and International Menopause Society position paper argues that care for these women remains fragmented and delayed, and too often borrows caution from studies of women in their 60s and 70s.
Sources: ESHRE, ASRM, CREWHiRL and IMS Guideline Group on POI. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065. Free full text → · ESHRE patient guide (PDF) → · FIGO/IMS 2026 position paper →
Headline vs. Evidence
Before you forward a health headline, ask three questions: Was it a randomized trial or an observation? Did it measure a real outcome (a diagnosis, a fracture, a death) or a number on a lab report? And who was studied? Does that include someone like you? Here’s how this week’s women’s health stories score.
- Menopause timingHeadline: “Early menopause damages your brain.” Evidence: Earlier menopause tracked with modestly faster memory decline and more small-vessel changes over 18 years. Verdict: A real risk marker, not a sentence. Vascular risk factors are the lever you control.
- FDA labelHeadline: “Hormone therapy is now safe.” Evidence: The boxed warnings were removed because they overstated risk for women starting near menopause. Verdict: Safer framing, not zero risk. Timing, route, and personal history still decide.
- Estrogen & Alzheimer’sHeadline: “Estrogen prevents Alzheimer’s.” Evidence: Fewer Alzheimer’s changes at autopsy in older women on oral estrogen-only therapy; observational. Verdict: Encouraging, not proven. Not a reason to start hormones for memory alone.
- Dementia riskHeadline: “Hormone therapy causes dementia.” Evidence: That signal came from women starting at 65+. Started near menopause, trials and pooled data show no cognitive harm. Verdict: Outdated for most women who start in their 40s or 50s.
- Early menopauseHeadline: “You don’t need hormones if you feel fine.” Evidence: For menopause before 40–45, guidelines recommend therapy until about age 51 regardless of symptoms. Verdict: False for this group. Know your age at menopause.
The Long View
Menopause is a biomarker, and hormone optimization should be read like one
For most of modern medicine, menopause has been treated as a symptom problem: hot flashes to manage, then a chapter to close. This week’s study suggests a different frame. The age at which menopause arrives is information, a midlife reading of how a woman’s biology is aging, recorded decades before memory changes would ever appear.
Seen that way, menopause belongs next to the other numbers we use to predict the future: blood pressure, Lp(a), APOE genotype, coronary calcium, bone density. None of them is destiny. Each one tells us where to look harder and when to start.
That is also how we think about hormone optimization. The phrase has been stretched online to mean chasing a “youthful” number on a lab report. Evidence-based optimization is narrower and more useful. It means starting at the right time: the benefit–risk balance is most favorable before 60 or within 10 years of menopause, and hormone therapy is recommended for women with early menopause. It means choosing the right form: FDA-approved, body-identical estradiol, often as a patch or gel, which carries a lower clot risk than pills, and micronized progesterone to protect the uterus. It means treating the right target: symptoms, sleep, bone, genitourinary health, and, when it is specifically indicated, low desire that responds to carefully dosed testosterone. And it means monitoring and revisiting the plan every year rather than setting it once and forgetting it.
It also means being honest about what hormones don’t do. They are not, on current evidence, a dementia-prevention drug for most women. Custom-compounded products have not been tested with the same rigor as FDA-approved preparations. The brain-protection strategy with the strongest evidence is still vascular: control blood pressure, glucose and lipids, stay fit, sleep well, and don’t smoke.
The real opportunity is integration. A woman who reached menopause at 44, carries an APOE4 allele, and has rising blood pressure has a very different risk profile than a woman who reached menopause at 53 with none of those. Averages can’t see that difference. Genetics, biomarkers, DEXA body composition, and a careful history can. Your menopause is part of your data. It deserves a physician who reads it that way.
Do This Week
- 1Write down your age at menopause, and make sure your doctor has it. Include whether it was natural or followed surgery or cancer treatment. It is one of the few free, midlife predictors of future brain, bone and heart risk, and it is often missing from the chart.
- 2Menopause before 45? Ask directly about hormone therapy. Guidelines recommend it for most women with premature or early menopause until around age 51, even without symptoms. If you were told to stop or never offered it, revisit the conversation.
- 3In your 40s or 50s with symptoms? Don’t wait out the window. Hot flashes, night sweats, broken sleep and vaginal dryness are treatable. The benefit–risk balance is most favorable when therapy starts before 60 or within 10 years of your last period. Explore hormone therapy at Everhealth.
- 4Know your blood pressure, and treat it like brain medicine. The strongest imaging signal in this week’s study was small-vessel damage, and high blood pressure is its leading driver. Check at home for a week. Readings consistently at or above 130/80 are worth a conversation.
- 5Protect bone and muscle through the transition. Bone loss accelerates in the years around menopause. Lift weights at least twice a week, get enough protein and calcium, and ask whether a DEXA scan is due, especially after early menopause.
Questions We Got This Week
Does early menopause increase dementia risk?
It appears to be associated with modestly higher risk. An 18-year study of 2,603 women published in JAMA Network Open in 2026 found that each year earlier menopause occurred was linked to slightly faster decline in memory and overall thinking, an earlier Alzheimer’s diagnosis (about 1.8 fewer Alzheimer’s-free years for menopause 10 years earlier), and more small-vessel changes on brain MRI. The study shows association, not cause; earlier menopause may be a marker of faster aging overall. Controlling blood pressure, glucose, cholesterol, fitness and sleep remains the best-proven way to protect the brain.
Does hormone therapy cause dementia?
For women who start near menopause, the best evidence says no. The dementia warning came from the WHI Memory Study, which enrolled women aged 65 and older. A 2025 Lancet Healthy Longevity meta-analysis of 15 studies found no evidence that hormone therapy increases or decreases dementia risk, and the randomized KEEPS trial found no long-term effect on cognition about 10 years after women took hormones in early menopause. The FDA removed the dementia boxed warning in 2026. Hormone therapy is not recommended solely to prevent dementia.
Why did the FDA remove the black box warning on hormone therapy?
The FDA concluded that the 2003 boxed warnings, based on Women’s Health Initiative data from mostly older women, overstated risk for women starting therapy near menopause. Labeling approved on February 12, 2026 removed boxed warnings about cardiovascular disease, breast cancer and probable dementia, and advises considering therapy within 10 years of menopause or before age 60. The boxed warning about endometrial cancer with estrogen-only therapy in women with a uterus remains. Individual risks, including blood clots, stroke and breast cancer history, still need to be reviewed with a physician.
Should women with early menopause take hormone therapy?
In most cases, yes. For premature ovarian insufficiency (menopause before 40), the 2024 international guideline from ESHRE, ASRM and the International Menopause Society recommends hormone therapy from diagnosis until at least the usual age of menopause, about 51, whether or not symptoms are present, to reduce long-term risks to bone, heart and brain. Women with early menopause between 40 and 45 are generally advised similarly. Women with a history of hormone-sensitive cancer or blood clots need individualized specialist advice.
What is evidence-based hormone optimization for women?
It means prescribing the right hormone, in the right form, at the right time, for the right reason, and monitoring the result. For most women that means FDA-approved body-identical estradiol (often a transdermal patch or gel, which carries lower clot risk than pills), micronized progesterone if the uterus is present, and vaginal estrogen for genitourinary symptoms. Testosterone has good evidence only for low sexual desire causing distress in postmenopausal women. Custom-compounded hormones are not tested to the same standards as FDA-approved products and are not recommended routinely.
Is it too late to start hormone therapy after 60?
Not always, but the balance changes. Risks of stroke, blood clots and heart events are higher when systemic therapy is started after 60 or more than 10 years after menopause, which is why current labeling and the Menopause Society emphasize earlier initiation. Women over 60 with persistent symptoms may still be candidates after careful review, often at lower doses or with transdermal estrogen. Low-dose vaginal estrogen for dryness and urinary symptoms has minimal systemic absorption and can be appropriate at any age.
Saw a headline that worried you?
Bring it to your next Everhealth visit. We’ll translate the study into what it means for your biology, your medications, and your plan.
Turn your menopause into a prevention plan
Hormone, cardiometabolic, genetic, and brain-risk testing, interpreted by a physician in one integrated, numbered action plan.
Schedule an AssessmentKnow a woman in her 40s or 50s, or someone who went through early menopause? Forward her this edition. · Further reading: The Menopause Society 2022 Hormone Therapy Position Statement · Global Consensus on Testosterone Therapy for Women · Missed Issue 10? Read it here.